Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology has disclosed Non-Current Deferred Tax Liability across 6 years of filings, most recently posting $3.3 million for Q1 2023.

• Non-Current Deferred Tax Liability for Q1 2023 came in at $3.3 million, down 82.36% year-over-year; the trailing twelve-month figure through Mar 2023 was $3.3 million (down 82.36% YoY), and the FY2022 annual result was $3.3 million, down 82.36% from the prior year.
• Non-Current Deferred Tax Liability came in at $3.3 million for Q1 2023 at Vir Biotechnology, roughly flat from $3.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $18.4 million in Q4 2021 to a low of $3.3 million in Q4 2020.
• The 5-year median for Non-Current Deferred Tax Liability is $3.3 million (2019), against an average of $7.3 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 466.83% in 2021 and plunged 82.36% in 2022, its largest moves.
• Vir Biotechnology's Non-Current Deferred Tax Liability stood at $3.3 million in 2019, then slipped by 1.57% to $3.3 million in 2020, then soared by 466.83% to $18.4 million in 2021, then slumped by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $3.3 million (Q1 2023), $3.3 million (Q4 2022), and $18.4 million (Q3 2022), per Business Quant data.